

ORAL COMMUNICATIONS

WEDNESDAY, 11 JULY 2007

15:45 - 17:15

Prognosis of venous thromboembolism II

Plenary Hall

Chairpersons: J. Douketis (CA), D. Wahl (FR)

- O-W-055 **THE NATURAL HISTORY OF D-DIMER LEVELS IN SUBJECTS WITH NEGATIVE D-DIMER AFTER SUSPENSION OF ORAL ANTICOAGULATION FOR A FIRST EPISODE OF VENOUS THROMBOEMBOLISM: THE PROSPECTIVE OBSERVATIONAL PROLONG II STUDY**
B. Cosmi* (IT), C. Legnani, E. Favaretto, L. Valdrè, M. Frascaro, G. Guazzaloca, A. Tripodi, F. Marongiu, G. Palareti 15:45 - 16:00
- O-W-056 **DEEP VEIN THROMBOSIS AND THE RISK OF RECURRENT PULMONARY EMBOLISM**
D. Jimenez* (ES), G. Díaz, R. Vidal, E. Marin, E. Aracil, A. Sueiro, R. D. Yusen 16:00 - 16:15
- O-W-057 **PROGNOSTIC VALUE OF TROPONINS IN ACUTE PULMONARY EMBOLISM: A META-ANALYSIS**
C. Becattini (IT), M. C. Vedovati*, G. Agnelli 16:15 - 16:30
- O-W-058 **THE RISK OF FATAL PULMONARY EMBOLISM AFTER STOPPING ANTICOAGULANT THERAPY IN PATIENTS WITH VENOUS THROMBOEMBOLISM**
C. Gu (CA), S. Schulman, A. Ghirarduzzi, V. Pengo, P. Prandoni, J. Douketis* 16:30 - 16:45
- O-W-059 **CARDIOVASCULAR RISK FACTORS AND VENOUS THROMBOEMBOLISM: A META-ANALYSIS**
W. Ageno* (IT), C. Becattini, T. Brighton, R. Selby, P. W. Kamphuisen 16:45 - 17:00
- O-W-060 **VENOUS THROMBOEMBOLISM AND SUBSEQUENT HOSPITALIZATION DUE TO ACUTE CARDIOVASCULAR EVENTS. A 20 YEARS FOLLOW-UP STUDY**
H. T. Sorensen* (DK), E. Horvath-Puho, L. Pedersen, J. A. Baron, P. Prandoni 17:00 - 17:15

Von Willebrand factor and disease

Room A/B

Chairpersons: Z. M. Ruggeri (US), A. Srivastava (IN)

- O-W-061 **MODULATION OF VON WILLEBRAND A1 DOMAIN FUNCTION BY THE HOMOLOGOUS DOMAINS A2 AND A3**
G. M. Podda* (US), J. R. Roberts, Z. M. Ruggeri 15:45 - 16:00
- O-W-062 **N-LINKED GLYCOSYLATION OF VWF MODULATES THE INTERACTION WITH ADAMTS13**
T. A. J. McKinnon* (UK), A. Chion, M. A. Laffan 16:00 - 16:15
- O-W-063 **VWF A2 DOMAIN SEQUENCE 1533-1553: ITS ROLE IN CONTROLLING ADAMTS13 ACCESS TO THE Y1605-M1606 SCISSILE BOND**
S. Zanardelli (UK), C. K. N. K. Chion, J. T. B. Crawley, R. Moss, D. A. Lane, A. Chion* 16:15 - 16:30

ORAL COMMUNICATIONS

WEDNESDAY, 11 JULY 2007

15:45 - 17:15

- O-W-064 **A HIGHLY-SENSITIVE PLASMA VON WILLEBRAND FACTOR (VWF): RISTOCETIN COFACTOR ACTIVITY ASSAY BY FLOW CYTOMETRY**
D. Chen* (US), R. K. Pruthi, W. L. Nichols, J. A. Heit, W. G. Owen 16:30 - 16:45
- O-W-065 **A COMMON LARGE DELETION OF VWF IN GERMAN AND ITALIAN PATIENTS WITH SEVERE VON WILLEBRAND DISEASE TYPE 3**
R. Schneppenheim* (DE), G. Castaman, A. B. Federici, M. Franchini, W. Kreuz, R. Marschalek, J. Oldenburg, T. Obser, F. Oyen, U. Budde 16:45 - 17:00
- O-W-066 **THE INFLUENCE OF INTRON 1 SEQUENCE VARIATIONS IN MUTATION-NEGATIVE TYPE 1 VON WILLEBRAND DISEASE PATIENTS**
M. Othman* (CA), Y. Chirinian, C. Brown, D. Lillicrap 17:00 - 17:15

New anticoagulants

Room C

Chairpersons: *R. Bauersachs (DE), B. I. Eriksson (SE)*

- O-W-049 **DABIGATRAN ETEXILATE IS EFFECTIVE AND SAFE FOR THE EXTENDED PREVENTION OF VENOUS THROMBOEMBOLISM FOLLOWING TOTAL HIP REPLACEMENT**
B. I. Eriksson* (SE), O. E. Dahl, N. Rosencher, A. A. Kurth, N. V. Dijk, S. P. Frosticks, R. Hettiarachchi, S. Hantel, J. Schnee, H. R. Büller 15:45 - 16:00
- O-W-050 **THE ORAL DIRECT THROMBIN INHIBITOR, DABIGATRAN ETEXILATE, IS EFFECTIVE AND SAFE FOR PREVENTION OF MAJOR VENOUS THROMBOEMBOLISM FOLLOWING MAJOR ORTHOPEDIC SURGERY**
J. A. Caprini* (US), E. Hwang, S. Hantel, J. Schnee, B. I. Eriksson 16:00 - 16:15
- O-W-051 **DABIGATRAN ETEXILATE VERSUS ENOXAPARIN IN PREVENTING VENOUS THROMBOEMBOLISM FOLLOWING TOTAL KNEE ARTHROPLASTY**
R. J. Friedman* (US), J. A. Caprini, P. C. Comp, B. L. Davidson, C. W. Francis, J. Ginsberg, M. Huo, J. Lieberman, J. E. Muntz, G. E. Raskob, M. L. Clements, S. Hantel, J. Schnee 16:15 - 16:30
- O-W-052 **TREATMENT OF PROXIMAL DEEP VEIN THROMBOSIS (DVT): RIVAROXABAN ONCE OR TWICE DAILY HAD SIMILAR EFFICACY AND SAFETY TO STANDARD THERAPY IN PHASE II STUDIES**
H. R. Büller* (NL), G. Agnelli 16:30 - 16:45
- O-W-053 **SAFETY AND TOLERABILITY OF THE ORAL DIRECT THROMBIN INHIBITOR AZD0837 IN PREVENTION OF STROKE AND OTHER THROMBOEMBOLIC COMPLICATIONS ASSOCIATED WITH ATRIAL FIBRILLATION (AF)**
B. Olsson* (SE), L. H. Rasmussen, A. Tveit, E. Jensen, P. Wessman, S. Panfilov, H. D. Ekdal, K. Wählander 16:45 - 17:00
- O-W-054 **ONCE-WEEKLY SUBCUTANEOUS IDRAPARINUX (ANTI-XA) VERSUS ORAL VITAMIN K ANTAGONIST THERAPY FOR THE PREVENTION OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION**
H. Büller* (NL) for the AMADEUS Investigators 17:00 - 17:15